Tony Meehan

Chief Business Officer

Dr. Meehan has been working with large public and venture backed start-up pharmaceutical companies for 25 years, including Merck, Johnson & Johnson, TetraLogic Pharmaceuticals, and TransForm Pharmaceuticals. Tony has played leadership roles across business development, corporate venture, finance, product development, and manufacturing. He has helped raise over $150MM in investment capital, and led teams responsible for the development of over 50 investigational molecules and 8 new product registrations, including GARDISIL®, RotaTeq®, and VIOXX®. Tony holds an M.B.A from the Wharton School of the University of Pennsylvania, a Ph.D. from Carnegie Mellon University and a B.S.E from the University of Pennsylvania.